<SEC-DOCUMENT>0001716774-26-000021.txt : 20260729
<SEC-HEADER>0001716774-26-000021.hdr.sgml : 20260729
<ACCEPTANCE-DATETIME>20260729094808
ACCESSION NUMBER:		0001716774-26-000021
CONFORMED SUBMISSION TYPE:	SCHEDULE 13G
PUBLIC DOCUMENT COUNT:		1
FILED AS OF DATE:		20260729
DATE AS OF CHANGE:		20260729

SUBJECT COMPANY:	

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ProQR Therapeutics N.V.
		CENTRAL INDEX KEY:			0001612940
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				000000000
		STATE OF INCORPORATION:			P7
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		SCHEDULE 13G
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	005-88671
		FILM NUMBER:		261214330

	BUSINESS ADDRESS:	
		ADDRESS IS A NON US LOCATION: 	YES
		STREET 1:		ZERNIKEDREEF 9
		CITY:			LEIDEN
		PROVINCE COUNTRY:   	P7
		BUSINESS PHONE:		31 88 166 7000

	MAIL ADDRESS:	
		ADDRESS IS A NON US LOCATION: 	YES
		STREET 1:		ZERNIKEDREEF 9
		CITY:			LEIDEN
		PROVINCE COUNTRY:   	P7

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ProQR Therapeutics B.V.
		DATE OF NAME CHANGE:	20140708

FILED BY:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Aberdeen Group plc
		CENTRAL INDEX KEY:			0001716774
		ORGANIZATION NAME:           	
		EIN:				000000000
		STATE OF INCORPORATION:			X0
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		SCHEDULE 13G

	BUSINESS ADDRESS:	
		STREET 1:		1 GEORGE STREET
		CITY:			EDINBURGH
		STATE:			X0
		ZIP:			EH2 2LL
		BUSINESS PHONE:		0131 245 2552

	MAIL ADDRESS:	
		STREET 1:		1 GEORGE STREET
		CITY:			EDINBURGH
		STATE:			X0
		ZIP:			EH2 2LL

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	abrdn plc
		DATE OF NAME CHANGE:	20210707

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Standard Life Aberdeen plc
		DATE OF NAME CHANGE:	20170912
</SEC-HEADER>
<DOCUMENT>
<TYPE>SCHEDULE 13G
<SEQUENCE>1
<FILENAME>primary_doc.xml
<TEXT>
<XML>
<?xml version="1.0" encoding="UTF-8"?><edgarSubmission xmlns="http://www.sec.gov/edgar/schedule13g" xmlns:ns1="http://www.sec.gov/edgar/common">
  <schemaVersion>X0202</schemaVersion>
<headerData>
    <submissionType>SCHEDULE 13G</submissionType>
    <filerInfo>
      <filer>
        <filerCredentials>
          <cik>0001716774</cik>
          <ccc>XXXXXXXX</ccc>
        </filerCredentials>
      </filer>
      <liveTestFlag>LIVE</liveTestFlag>



    </filerInfo>
  </headerData>
  <formData>
    <coverPageHeader>
      <securitiesClassTitle>Ordinary Shares, nominal value EUR0.04 per share</securitiesClassTitle>
      <eventDateRequiresFilingThisStatement>06/30/2026</eventDateRequiresFilingThisStatement>
      <issuerInfo>
        <issuerCik>0001612940</issuerCik>
        <issuerName>ProQR Therapeutics NV</issuerName>
        <issuerCusips>
          <issuerCusipNumber>N71542109</issuerCusipNumber>
        </issuerCusips>
        <issuerPrincipalExecutiveOfficeAddress>
          <ns1:street1>Zernikedreef 9</ns1:street1>
          <ns1:street2>Leiden</ns1:street2>
          <ns1:city>The Netherlands</ns1:city>
          <ns1:stateOrCountry>XX</ns1:stateOrCountry>
          <ns1:zipCode>CK 2333</ns1:zipCode>
        </issuerPrincipalExecutiveOfficeAddress>
      </issuerInfo>
      <designateRulesPursuantThisScheduleFiled>
        <designateRulePursuantThisScheduleFiled>Rule 13d-1(b)</designateRulePursuantThisScheduleFiled>
      </designateRulesPursuantThisScheduleFiled>
    </coverPageHeader>
    <coverPageHeaderReportingPersonDetails>


      <reportingPersonName>Aberdeen Group plc</reportingPersonName>
      <citizenshipOrOrganization>X0</citizenshipOrOrganization>
      <reportingPersonBeneficiallyOwnedNumberOfShares>
        <soleVotingPower>0</soleVotingPower>
        <sharedVotingPower>8932507</sharedVotingPower>
        <soleDispositivePower>0</soleDispositivePower>
        <sharedDispositivePower>8932507</sharedDispositivePower>
      </reportingPersonBeneficiallyOwnedNumberOfShares>
      <reportingPersonBeneficiallyOwnedAggregateNumberOfShares>8932507</reportingPersonBeneficiallyOwnedAggregateNumberOfShares>
      <aggregateAmountExcludesCertainSharesFlag>N</aggregateAmountExcludesCertainSharesFlag>
      <classPercent>6.33</classPercent>
      <typeOfReportingPerson>HC</typeOfReportingPerson>
    </coverPageHeaderReportingPersonDetails>
    <coverPageHeaderReportingPersonDetails>
      <reportingPersonName>abrdn Inc.</reportingPersonName>
      <citizenshipOrOrganization>X1</citizenshipOrOrganization>
      <reportingPersonBeneficiallyOwnedNumberOfShares>
        <soleVotingPower>0</soleVotingPower>
        <sharedVotingPower>8932507</sharedVotingPower>
        <soleDispositivePower>0</soleDispositivePower>
        <sharedDispositivePower>8932507</sharedDispositivePower>
      </reportingPersonBeneficiallyOwnedNumberOfShares>
      <reportingPersonBeneficiallyOwnedAggregateNumberOfShares>8932507</reportingPersonBeneficiallyOwnedAggregateNumberOfShares>
      <aggregateAmountExcludesCertainSharesFlag>N</aggregateAmountExcludesCertainSharesFlag>
      <classPercent>6.33</classPercent>
      <typeOfReportingPerson>CO</typeOfReportingPerson>
      <typeOfReportingPerson>IA</typeOfReportingPerson>
    </coverPageHeaderReportingPersonDetails>
    <items>
      <item1>
        <issuerName>ProQR Therapeutics NV</issuerName>
        <issuerPrincipalExecutiveOfficeAddress>Zernikedreef 9, Leiden, The Netherlands
CK 2333</issuerPrincipalExecutiveOfficeAddress>
      </item1>
      <item2>
        <filingPersonName>Aberdeen Group plc

abrdn Inc.</filingPersonName>
        <principalBusinessOfficeOrResidenceAddress>Aberdeen Group plc:
1 George Street
Edinburgh, United Kingdom
EH2 2LL

abrdn Inc.:
1900 Market Street, Suite 200
Philadelphia
PA 19103</principalBusinessOfficeOrResidenceAddress>
        <citizenship>Aberdeen Group plc - UNITED KINGDOM

abrdn Inc. - UNITED STATES</citizenship>
      </item2>
      <item3>
        <notApplicableFlag>N</notApplicableFlag>
        <typeOfPersonFiling>HC</typeOfPersonFiling>
      </item3>
      <item4>
        <amountBeneficiallyOwned>8,932,507</amountBeneficiallyOwned>
        <classPercent>6.33</classPercent>
        <numberOfSharesPersonHas>
          <solePowerOrDirectToVote>Aberdeen Group plc - 0

abrdn Inc. - 0</solePowerOrDirectToVote>
          <sharedPowerOrDirectToVote>Aberdeen Group plc - 8,932,507

abrdn Inc. - 8,932,507</sharedPowerOrDirectToVote>
          <solePowerOrDirectToDispose>Aberdeen Group plc - 0

abrdn Inc. - 0</solePowerOrDirectToDispose>
          <sharedPowerOrDirectToDispose>Aberdeen Group plc - 8,932,507

abrdn Inc. - 8,932,507</sharedPowerOrDirectToDispose>
        </numberOfSharesPersonHas>
      </item4>
      <item5>
        <notApplicableFlag>Y</notApplicableFlag>
      </item5>
      <item6>
        <notApplicableFlag>Y</notApplicableFlag>
      </item6>
      <item7>
        <notApplicableFlag>N</notApplicableFlag>
        <subsidiaryIdentificationAndClassification>See Exhibit</subsidiaryIdentificationAndClassification>
      </item7>
      <item8>
        <notApplicableFlag>Y</notApplicableFlag>
      </item8>
      <item9>
        <notApplicableFlag>Y</notApplicableFlag>
      </item9>
      <item10>
        <notApplicableFlag>N</notApplicableFlag>
        <certifications>By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.</certifications>
      </item10>
    </items>
    <exhibitInfo>Aberdeen Group plc
abrdn Holdings Limited
abrdn Inc.



Aberdeen Group plc is the parent company.
abrdn Holdings Limited is the intermediate holding company for abrdn Inc.
abrdn Inc. beneficially owns on behalf of our underlying clients 5% or greater of the outstanding shares of the security class being reported on this Schedule 13G.</exhibitInfo>
    <signatureInformation>
      <reportingPersonName>Aberdeen Group plc</reportingPersonName>
      <signatureDetails>
        <signature>R. Chaudhry</signature>
        <title>Romiza Chaudhry / Major Shareholding Reporting Analyst</title>
        <date>07/29/2026</date>
      </signatureDetails>
    </signatureInformation>
    <signatureInformation>
      <reportingPersonName>abrdn Inc.</reportingPersonName>
      <signatureDetails>
        <signature>R. Chaudhry</signature>
        <title>Romiza Chaudhry / Major Shareholding Reporting Analyst</title>
        <date>07/29/2026</date>
      </signatureDetails>
    </signatureInformation>
  </formData>
</edgarSubmission>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
